Publication date: Jul 01, 2025
The COVID-19 pandemic highlighted the vulnerability of pregnant women and newborns, emphasizing the importance of vaccination during pregnancy to protect mothers and their infants. Maternal vaccination generates robust anti-SARS-CoV-2 IgG antibodies, transferred to the fetus through the placenta, providing neonatal protection. Breastfeeding also transfers maternal antibodies (IgA and IgG), potentially enhancing mucosal immunity. This study aimed to evaluate neonatal antibody kinetics following maternal COVID-19 vaccination, comparing vaccinated nacEFve mothers to those previously infected. A monocentric prospective observational cohort study was conducted between July 2021 and July 2022, enrolling 44 mother-infant pairs at the Pediatrics Unit of Arzignano Cazzavillan Hospital. Eligible participants included mothers vaccinated during pregnancy (third trimester), either nacEFve or previously infected with SARS-CoV-2. Blood and breast milk samples were collected at birth and periodically up to six months postpartum. Neonatal cord blood and subsequent samples were analyzed for anti-SARS-CoV-2 spike (S1) IgG and IgA antibodies. Statistical analyses involved parametric and non-parametric tests, with significance set at p
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | IDO | blood |